Private equity and private credit funds, real estate limited partnerships, prospectus-exempt offerings, hedge funds, alternative mutual funds, and US Regulation D private placements have become a routine part of wealth management shelves. They are also where Know-Your-Product is hardest to do well. There's less public disclosure, fewer independent data sources, valuations that are estimated rather than observed, redemption terms that can change without notice, and - more often than elsewhere on the shelf - a relationship between the firm and the issuer.
Regulators on both sides of the border have been clear that the diligence has to scale with those features, not shrink because of them. In Canada, the joint CSA/CIRO staff notice says a more in-depth KYP review may be warranted for securities that are novel, not transparent in structure, use leverage or derivatives, have limited liquidity, or have limited disclosure available - a description that fits most of the alternatives shelf.[3] In the US, FINRA has repeatedly reminded broker-dealers that they must conduct a reasonable investigation of private placements they recommend and may not simply rely on what the issuer tells them.[7][8]
This paper sets out what product due diligence on an alternative or private market investment needs to cover, and what the firm and the individual advisor each have to do. It covers the regulatory basis in Canada and the US, eight areas the assessment should address, how to verify what issuers and sponsors say, the red flags that should stop or deepen a review, and what approval, monitoring and documentation look like for products that don't trade on an exchange.
Its scope is the product: what a firm and its registered individuals need to know about an alternative investment before it's offered and while it's held. Decisions about individual clients are outside it. For how significant changes are detected and escalated generally, see Material Change: When to Reopen a KYP Assessment.
Neither Canada nor the US has a separate KYP regime for alternatives. The same rules apply to every product. What changes is how much diligence those rules demand, and regulators in both countries have said it rises with complexity, opacity and illiquidity.
CIRO's Rule 3301 requires a dealer to take reasonable steps to assess, approve and monitor what it makes available, with the assessment covering the security's "structure, features, risks, initial and ongoing costs and the impact of those costs." Rule 3302 requires each Approved Person to take steps to understand the same elements before buying, selling or recommending it.[1] NI 31-103 section 13.2.1 applies the equivalent obligations to exempt market dealers and portfolio managers.[2]
Joint CSA/CIRO Staff Notice 31-368 is explicit that one level of review doesn't fit every product:
The notice gives an example of a firm practice that reflects this: dealers that set different KYP processes depending on, among other things, whether a proposed fund is a prospectus-qualified mutual fund or a prospectus-exempt alternative fund, with additional review for more costly funds.[3]
Several of the notice's KYP findings bear directly on alternatives:[3]
The notice lists the kinds of documents firms should keep to support a KYP assessment, including offering memoranda, financial statements, internal due diligence reports, performance reports, filings and disclosures - and records of the analysis itself. "These records are required to support the decision to make a security available to clients and demonstrate that a reasonable review was conducted prior to approving the securities."[3] Its list of what KYP policies should cover also names two elements that matter more for alternatives than almost anywhere else: the parties involved in the security, such as the issuer's management, portfolio manager, guarantors or significant counterparties, and any conflicts of interest inherent in the security.[3]
The US has the most developed body of guidance on product diligence for private offerings, built largely through FINRA notices on Regulation D private placements.
FINRA Regulatory Notice 10-22 set out the core position: broker-dealers have a duty to conduct a reasonable investigation of securities they recommend, including those sold in Regulation D offerings, and may not "rely blindly upon the issuer" for information about the company.[7] The notice describes practices for investigating the issuer and its management, its business prospects, and its assets, and says that red flags call for further inquiry rather than reliance on management's representations. It also expects a broker-dealer affiliated with an issuer to ensure the affiliation doesn't compromise the independence of its investigation.[7]
Regulatory Notice 23-08 restated those expectations under Reg BI. It lists the areas a reasonable investigation should address - including the issuer and its management, business prospects, assets, claims being made and intended use of proceeds - and cautions firms to review third-party due diligence reports with reasonable care, considering the independence, incentives and qualifications of their authors.[8]
The first component of Reg BI's Care Obligation requires a broker-dealer to understand the potential risks, rewards and costs of a recommended security or strategy.[5][6] For an alternative investment, that understanding depends on the reasonable investigation FINRA describes; without it, the firm can't show it understood what it recommended.
The SEC's 2019 interpretation of the adviser standard of conduct requires an adviser to "conduct a reasonable investigation into the investment sufficient not to base its advice on materially inaccurate or incomplete information."[4] For products with limited disclosure, meeting that standard usually means obtaining and verifying information beyond what the sponsor volunteers.
FINRA Regulatory Notice 12-03 on complex products lists questions firms should consider before approving one, including whether its investment objective is reasonable, what assumptions underlie it and how it is expected to perform across a wide variety of market scenarios, whether it presents novel risks, how the firm is compensated for offering it, and how liquid it is. It also expects firms to reassess complex products periodically after approval.[9] Many alternative investments meet its description of complex products.
| KYP Question for an Alternative | Canada (CIRO / CSA) | United States |
|---|---|---|
| How deep must the assessment go? | Deeper for products that are novel, opaque, leveraged, illiquid or thinly disclosed | A reasonable investigation, scaled to the product and to any red flags |
| Can the firm rely on issuer or third-party material? | It can use it, but must document its own analysis | Not blindly; third-party reports must be reviewed with reasonable care |
| What about related or affiliated issuers? | Same or similar KYP process as for unrelated issuers | The affiliation must not compromise the independence of the investigation |
| Is ongoing monitoring expected? | Yes; annual monitoring alone was found inadequate for risky, illiquid products | Implied by the product-understanding duties; FINRA expects periodic reassessment of complex products |
The regulatory elements are the same for every product - structure, features, risks, costs, the parties involved, and conflicts. For alternatives, each of those breaks out into questions a mutual fund review never has to ask.
The table maps the regulatory elements to the specific questions they raise for alternatives, and to the evidence that answers them. It's a framework for building a firm's own assessment template, not a prescribed checklist; the depth applied to each area should match the product.
| Area | Key Questions | Typical Evidence |
|---|---|---|
| Structure and terms | What is the legal vehicle? What do investors actually own? What are the term, lock-up, capital call and distribution provisions? What can the sponsor change without investor consent? | Offering memorandum, limited partnership or trust agreement, subscription documents |
| Sponsor, manager and parties | Who runs it, and what is their track record, ownership and financial strength? Who are the auditor, administrator, custodian, valuation agent and legal counsel, and are they independent and recognized? | Manager due diligence questionnaire, biographies, regulatory registration checks, service provider confirmations |
| Strategy and assets | What does the product invest in, and how? Does the portfolio match the stated strategy? What leverage is used, at what level and on what terms? | Portfolio holdings or asset schedules, investment policy, leverage and borrowing disclosures |
| Valuation | How are assets valued, how often, by whom, and with what inputs? Is valuation independent of the manager? How have reported values compared with realized exits or third-party appraisals? | Valuation policy, audited financial statements, appraisals, NAV history |
| Liquidity and redemption | How and when can investors exit? What gates, suspensions, notice periods or penalties apply? How do the product's liquidity terms compare with the liquidity of its assets? | Redemption provisions, history of any gating or suspension, secondary market availability |
| Costs | What is the full cost stack - management fees, performance fees or carried interest, fund expenses, organizational costs, placement or selling fees, trailing commissions - and how do they affect returns? | Fee schedules in the offering documents, financial statements, dealer compensation disclosure |
| Conflicts and related parties | Is the firm, or anyone connected to it, related to the issuer? Are there related-party transactions inside the product? How is the firm compensated for distributing it? | Related and connected issuer disclosures, related-party transaction notes, compensation arrangements |
| Disclosure and history | How often and how fully does the product report to investors? Are financial statements audited, and on time? What is the regulatory and litigation history of the sponsor and its principals? | Investor reports, audit opinions and filing dates, regulator databases, litigation searches |
Two areas deserve particular attention because they're where alternatives differ most from listed products. Valuation determines every performance number a firm or advisor will see; if it's set by the manager with little independent check, the reported returns and volatility are estimates, and the assessment should say so. Liquidity is the feature most likely to change after approval, and the one that most limits what the firm can do if something goes wrong.
Most information about a private investment comes from the party selling it. Both regulators have said that isn't enough on its own: Canadian staff expect the firm to document its own analysis rather than rely on third-party material,[3] and FINRA says a broker-dealer may not rely blindly on the issuer.[7] Verification doesn't mean re-auditing the product. It means confirming the claims the assessment depends on through a source other than the sponsor. Common approaches include:
What matters for KYP is that the assessment records which facts were verified, how, and which rest on the sponsor's word alone. A reader of the file should be able to tell the difference.
FINRA's guidance treats red flags as a trigger for further inquiry, not something to be noted and passed over.[7][8] A firm's assessment template should list the red flags it looks for and say what each requires. The list below is representative.
| Red Flag | Why It Matters | Typical Response |
|---|---|---|
| Auditor unknown, small relative to the product, or recently changed | The audit is the main independent check on the financial statements and valuations | Confirm the auditor directly; understand the reason for any change |
| Late or qualified audited financial statements | Signals accounting, valuation or going-concern issues | Do not approve, or suspend, until resolved and explained |
| Valuation set by the manager with no independent review | Reported returns and risk may not reflect realizable value | Require evidence of independent valuation or disclose the limitation in the assessment |
| Returns that are unusually smooth or high for the strategy | Can indicate stale valuations or misrepresented performance | Test against audited results and comparable products |
| Material related-party transactions | Creates conflicts inside the product that may not favour investors | Assess terms and oversight; record the conflict in the assessment |
| Liquidity terms more generous than the assets can support | Raises the likelihood of gating or suspension under stress | Assess redemption mechanics and the sponsor's liquidity management |
| Regulatory or litigation history of the sponsor or principals | Bears on the integrity and competence of the people running it | Review the history and obtain an explanation before proceeding |
| Reluctance to provide documents or access | Limits the firm's ability to complete a reasonable review | Treat incomplete access as a reason not to approve |
An alternative investment's KYP doesn't end when it's approved. It runs through approval, monitoring and documentation, with responsibilities at both the firm and the individual level.
In the KYP HubHow products are approved onto the shelf, whatever their type: Product Approval.
The notice expects approval documentation to show "meaningful consideration" by whoever approves a security, including the key elements assessed and support for why approval was appropriate.[3] It observed that at many larger firms, complex or high-risk products are reviewed and approved by a product review committee, and that firms specializing in niche sectors rely on assessments by people with relevant expertise.[3] For alternatives, both practices usually apply.
In the KYP HubHow monitoring rules, the engine and alerts work: Material Change. What happens when an alert fires: From Alert to Decision. When a change should reopen KYP: Material Change: When to Reopen a KYP Assessment. The same lifecycle for other security types: equities, mutual funds and ETFs, structured products, segregated funds and annuities and model portfolios.
Alternatives are harder to monitor than listed products for a structural reason: the data arrives late. NAVs may be struck quarterly, audited statements months after year-end, and material events may only surface in an investor letter. That makes the notice's findings more pointed, not less - annual monitoring of risky, illiquid products was found inadequate, and waiting for the issuer to report change was a deficiency in its own right.[3] Monitoring for alternatives relies heavily on event triggers rather than market-data thresholds. Typical significant changes include:
Where a product's illiquidity limits what can be done, the notice says appropriate responses may involve halting new sales.[3] That decision, and the assessment behind it, still has to be documented and communicated to everyone who offers the product.
In the KYP HubWhat the KYP file must show: KYP Documentation: What Your File Must Show. How supervision tests it: Supervising a KYP Program.
The example below shows what a written process for alternatives might cover. It's illustrative; the notice is clear that processes can vary with a firm's business model and the complexity and risks of what it offers.[3]